GlassScriptPhysician profile
Sharif A Halim
NPI 1730355546
$22,320.57
in general payments reported to CMS, 2019-2025
21 companies · $5,148 in 2025
The $5,148 reported for 2025 was more than what 83% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,960 · 2020: $538 · 2021: $1,714 · 2022: $1,028 · 2023: $4,050 · 2024: $4,883 · 2025: $5,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,704 · Travel and Lodging: $4,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,704.12 |
| Travel and Lodging | $4,377.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $5,938.08 | 2019-2025 | Impella |
| Abbott Laboratories | $4,932.63 | 2019-2025 | Navitor, Amplatzer Amulet, Mitraclip |
| Edwards Lifesciences Corporation | $3,799.68 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve, Pascal |
| Boston Scientific Corporation | $2,310.38 | 2019-2025 | Watchman Flx, Watchman Access System, Watchman |
| Medtronic Vascular, INC. | $1,784.86 | 2019-2020 | |
| Cardiovascular Systems INC. | $1,121.84 | 2019-2023 | Diamondback Coronary |
| Medtronic, INC. | $761.95 | 2021-2025 | Corevalve Evolut R, Onyx Frontier |
| Philips North America LLC | $310.76 | 2020-2023 | |
| Stryker Corporation | $243.72 | 2025 | Flowtriever |
| E.R. Squibb & Sons, L.L.C. | $232.71 | 2019-2025 | Camzyos, Eliquis |
| Shockwave Medical, INC | $219.98 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $170.82 | 2019-2025 | Repatha |
| W. L. Gore & Associates, INC. | $157.80 | 2021-2023 | Gore Cardioform Septal Occluder |
| Novartis Pharmaceuticals Corporation | $82.80 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $66.70 | 2019-2024 | Xarelto |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.06 | 2021-2024 | Lifevest |
| Pfizer INC. | $46.03 | 2020-2024 | |
| Cardiva Medical, INC. | $34.19 | 2025 | Ensoetm |
| Chiesi USA, INC. | $25.44 | 2020-2024 | Cleviprex, Kengreal |
| Inari Medical, INC. | $18.06 | 2021 | |
| Angiodynamics, INC. | $14.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharif Halim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.